arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MAXCYTE, INC.

MXCT
$1.20 ▼ -0.04 (-3.23%) at close
Industrials ·Services-Commercial Physical & Biological Research ·USServices-Commercial Physical & Biological Research
28 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

MAXCYTE, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $128.2M
Dividend Yield —
Revenue Growth -14.5% ↘
Op. Margin -140.7% ↘
ROIC -5.1% ↘
FCF / Share $-0.04 ↗
Trailing P/E —
Price / Book 0.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

28-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.27M
↓ -14.5% —
Net Income Profit after all expenses
$-4.75M
↑ +53.7% —
Operating Margin Operating profit as % of sales
-140.7%
↓ -119.6% 1th
FCF / Share Free cash flow per share
$-0.04
↑ +42.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
2
Returns ↓
25
Cash Quality ↑
55

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 28 quarters